NEW YORK, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Decibel Therapeutics, Inc. (NASDAQ: DBTX)’s sale to Regeneron Pharmaceuticals, Inc. Under the terms of the merger, Decibel shareholders will receive $4.00 per share in cash and a non-tradeable contingent value right entitling such holders to receive up to $3.50 per share in cash if certain clinical development and regulatory milestones are achieved. If you are a Decibel shareholder, click here to learn more about your rights and options.
Amedisys, Inc. (NASDAQ: AMED)’s sale to Optum for $101.00 per share. If you are an Amedisys shareholder, click here to learn more about your rights and options.
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)’s sale to Biogen Inc. for $172.50 per share in cash. If you are a Reata shareholder, click here to learn more about your rights and options.
Surface Oncology, Inc. (NASDAQ: SURF)’s sale to Coherus BioSciences, Inc. If you are a Surface shareholder, click here to learn more about your rights and options.
Shareholders are encouraged to contact the firm free of charge to discuss their legal rights and options. Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email sadeh@halpersadeh.com or zhalper@halpersadeh.com.
Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Halper Sadeh LLC
Daniel Sadeh, Esq.
Zachary Halper, Esq.
(212) 763-0060
sadeh@halpersadeh.com
zhalper@halpersadeh.com
https://www.halpersadeh.com
